Download PDF
Am J Perinatol 2025; 42(07): 891-898
DOI: 10.1055/a-2437-0828
Original Article

Illicit Fentanyl in the Prenatal Period: A Significant Emerging Risk for Neonatal Opioid Withdrawal Syndrome

Divya Rana 
1   Division of Neonatology, Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee
,
Kan P. Gaston
1   Division of Neonatology, Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee
,
Linda DeBaer
1   Division of Neonatology, Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee
,
Massroor Pourcyrous
1   Division of Neonatology, Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee
2   Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, Memphis, Tennessee
3   Department of Physiology, University of Tennessee Health Science Center, Memphis, Tennessee
› Author Affiliations Funding None.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective

This study aimed to evaluate the impact of in-utero illicit fentanyl exposure on neonatal outcomes, including neonatal opioid withdrawal syndrome (NOWS), length of stay (LOS), and treatment requirements.

Study Design

This study was conducted from March 2020 to December 2022, and focused on neonates born to mothers with opioid use or opioid use disorder (OUD). Maternal opioid use was identified through self-report or umbilical cord tissue (UCT) testing. Severe NOWS was defined as cases requiring pharmacological treatment. Statistical analyses included univariate comparisons, logistic regression, and generalized linear models to assess the associations between fentanyl exposure and neonatal outcomes.

Results

Forty-seven percent (75/159) of infants had in-utero fentanyl exposure. Fentanyl-positive mothers were older, 31 ± 5 years, compared to non-fentanyl mothers, 29 ± 5, p = 0.01. They were also less likely to receive prenatal care (p < 0.01) and had a higher number of polysubstance used, 5 ± 1 compared to non-fentanyl mothers, 3 ± 1, p < 0.01. Overall, infants exposed to fentanyl had a higher incidence of severe NOWS (odds ratio = 5.8, 95% confidence interval [CI]: 2.49–12.95, p < 0.01) and required earlier NOWS treatment initiation, 1 ± 1 day compared to non-exposed infants 3 ± 2 days, p < 0.01. In adjusted analysis, fentanyl exposure was associated with a nearly three-fold increased risk of NOWS (Mantel–Haenszel combined relative risk = 2.98, 95% CI: 1.94–4.57). Furthermore, fentanyl exposure led to longer LOS, with a 40% increase for preterm neonates (p < 0.01) and a 63% increase for full-term neonates (p < 0.01). Additionally, there was a significant correlation between log fentanyl concentration in umbilical cord tissue and cumulative morphine dose required for NOWS treatment, p = 0.001.

Conclusion

Prenatal illicit fentanyl exposure is an independent and strong risk factor for severe NOWS presentation in newborns requiring extended hospital stays.

Key Points

  • Illicit fentanyl is increasingly recognized as a major driver of opioid-related substance use disorders during pregnancy, often occurring alongside polysubstance use.

  • Significant prenatal exposure to opioids is a well-established risk factor for neonatal opioid withdrawal syndrome. The recent rise in illicit fentanyl use has heightened these concerns.

  • Both preterm and term infants are at risk for severe withdrawal symptoms following prenatal exposure to illicit fentanyl.

Keywords

prenatal opioid exposure - illicit fentanyl - neonatal opioid withdrawal syndrome

Ethical Approval and Patient Consent

This study was approved by the IRB of the UTHSC. No consent form was required.




Publication History

Received: 06 September 2024

Accepted: 09 October 2024

Article published online:
29 October 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Pergolizzi J, Magnusson P, LeQuang JAK, Breve F. Illicitly manufactured fentanyl entering the United States. Cureus 2021; 13 (08) e17496
    PubMedSearch in Google Scholar
  • 2 Kilmer B, Pardo B, Pujol TA, Caulkins JP. Rapid changes in illegally manufactured fentanyl products and prices in the United States. Addiction 2022; 117 (10) 2745-2749
    CrossrefPubMedSearch in Google Scholar
  • 3 Mars SG, Rosenblum D, Ciccarone D. Illicit fentanyls in the opioid street market: desired or imposed?. Addiction 2019; 114 (05) 774-780
    CrossrefPubMedSearch in Google Scholar
  • 4 Palamar JJ, Ciccarone D, Rutherford C, Keyes KM, Carr TH, Cottler LB. Trends in seizures of powders and pills containing illicit fentanyl in the United States, 2018 through 2021. Drug Alcohol Depend 2022; 234: 109398
    CrossrefPubMedSearch in Google Scholar
  • 5 Gladden RM, O'Donnell J, Mattson CL, Seth P. Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine - 25 states, July-December 2017 to January-June 2018. MMWR Morb Mortal Wkly Rep 2019; 68 (34) 737-744
    CrossrefPubMedSearch in Google Scholar
  • 6 Galust H, Seltzer JA, Hardin JR. et al. Adulterants present in the San Diego county fentanyl supply: a laboratory analysis of seized law enforcement samples. BMC Public Health 2024; 24 (01) 923
    CrossrefPubMedSearch in Google Scholar
  • 7 Hwang SS, Diop H, Liu CL. et al. Maternal substance use disorders and infant outcomes in the first year of life among Massachusetts singletons, 2003-2010. J Pediatr 2017; 191: 69-75
    CrossrefPubMedSearch in Google Scholar
  • 8 Corsi DJ, Hsu H, Fell DB, Wen SW, Walker M. Association of maternal opioid use in pregnancy with adverse perinatal outcomes in Ontario, Canada, From 2012 to 2018. JAMA Netw Open 2020; 3 (07) e208256
    CrossrefPubMedSearch in Google Scholar
  • 9 Graeve R, Balalian AA, Richter M. et al. Infants' prenatal exposure to opioids and the association with birth outcomes: a systematic review and meta-analysis. Paediatr Perinat Epidemiol 2022; 36 (01) 125-143
    CrossrefPubMedSearch in Google Scholar
  • 10 ACOG Committee on Health Care for Underserved Women. American Society of Addiction Medicine. ACOG Committee Opinion No. 711: Opioid use and opioid use disorder in pregnancy. Obstet Gynecol 2017; 130: e81-e94
    CrossrefPubMedSearch in Google Scholar
  • 11 Socias ME, Wood E, Le Foll B. et al; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial. Addiction 2022; 117 (10) 2662-2672
    CrossrefPubMedSearch in Google Scholar
  • 12 Patrick SW, Barfield WD, Poindexter BB. Committee on Fetus and Newborn, Committee on Substance Use and Prevention. Neonatal opioid withdrawal syndrome. Pediatrics 2020; 146 (05) e2020029074
    CrossrefPubMedSearch in Google Scholar
  • 13 Merhar SL, Ounpraseuth S, Devlin LA. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network and the NIH Environmental Influences On Child Health Outcomes (ECHO) Program Institutional Development Awards States Pediatric Clinical Trials Network. Phenobarbital and clonidine as secondary medications for neonatal opioid withdrawal syndrome. Pediatrics 2021; 147 (03) e2020017830
    CrossrefPubMedSearch in Google Scholar
  • 14 Lien J, Hayes T, Liu-Smith F, Rana D. Comparing maternal substance use and perinatal outcomes before and during the COVID-19 pandemic. J Perinatol 2023; 43 (05) 664-669
    CrossrefPubMedSearch in Google Scholar
  • 15 Tennessee Department of Health. Annual Report on Substance Use in Tennessee. Nashville:: Tennessee Department of Health.; 2023
    Search in Google Scholar
  • 16 Tennessee Department of Health. Tennessee State Unintentional Drug overdose reporting. Accessed October 16, 2024 at: https://www.tn.gov/content/dam/tn/health/documents/pdo/sudors/SUDORS_Annual_Report_2024.pdf
    PubMed
  • 17 National Institute on Drug Abuse (NIDA). Overdose Death Rates. 2024 . Accessed October 16, 2024 at: https://www.drugabuse.gov https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates
    PubMedSearch in Google Scholar
  • 18 Tennessee Department of Health. Maternal mortality review: pregnancy-related deaths in Tennessee. . Morbidity and Mortality Weekly Report. 2023
    PubMed
  • 19 Nellhaus EM, Murray S, Hansen Z, Loudin S, Davies TH. Novel withdrawal symptoms of a neonate prenatally exposed to a fentanyl analog. J Pediatr Health Care 2019; 33 (01) 102-106
    CrossrefPubMedSearch in Google Scholar
  • 20 Morris E, Bardsley T, Schulte K. et al. Hospital outcomes of infants with neonatal opioid withdrawal syndrome at a tertiary care hospital with high rates of concurrent nonopioid (polysubstance) exposure. Am J Perinatol 2022; 39 (04) 387-393
    Thieme ConnectPubMedSearch in Google Scholar
  • 21 Decker CM, Mahar M, Howells CL, Ma ZQ, Goetz CT, Watkins SM. Demographics, birth parameters, and social determinants of health among opioid-exposed mother-infant dyads affected by neonatal abstinence syndrome in Pennsylvania, 2018-2019. Matern Child Health J 2023; 27 (Suppl. 01) 34-43
    CrossrefPubMedSearch in Google Scholar
  • 22 Simmons E, Austin AE. Association of prenatal substance use with prenatal and postpartum care: evidence from the Pregnancy Risk Assessment Monitoring System, 2016-2019. Prev Med 2022; 159: 107065
    CrossrefPubMedSearch in Google Scholar
  • 23 Kuczyńska K, Grzonkowski P, Kacprzak Ł, Zawilska JB. Abuse of fentanyl: an emerging problem to face. Forensic Sci Int 2018; 289: 207-214
    CrossrefPubMedSearch in Google Scholar
  • 24 Gryczynski J, Nichols H, Schwartz RP, Mitchell SG, Hill P, Wireman K. Fentanyl exposure and preferences among individuals starting treatment for opioid use disorder. Drug Alcohol Depend 2019; 204: 107515
    CrossrefPubMedSearch in Google Scholar
  • 25 Hochstatter KR, Terplan M, Mitchell SG. et al. Characteristics and correlates of fentanyl preferences among people with opioid use disorder. Drug Alcohol Depend 2022; 240: 109630
    CrossrefPubMedSearch in Google Scholar
  • 26 Jones CM, Bekheet F, Park JN, Alexander GC. The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms. Epidemiol Rev 2020; 42 (01) 154-166
    CrossrefPubMedSearch in Google Scholar
  • 27 Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants - United States, 2015-2016. MMWR Morb Mortal Wkly Rep 2018; 67 (12) 349-358
    CrossrefPubMedSearch in Google Scholar
  • 28 Coish R, Hardial J. Successful buprenorphine/naloxone low-dose induction in pregnancy: a case report. J Addict Med 2023; 17 (01) 114-116
    PubMedSearch in Google Scholar
  • 29 Smith BL, Hall ES, McAllister JM. et al. Rates of substance and polysubstance use through universal maternal testing at the time of delivery. J Perinatol 2022; 42 (08) 1026-1031
    CrossrefPubMedSearch in Google Scholar
  • 30 Young LW, Ounpraseuth ST, Merhar SL. et al; ACT NOW Collaborative. Eat, sleep, console approach or usual care for neonatal opioid withdrawal. N Engl J Med 2023; 388 (25) 2326-2337
    CrossrefPubMedSearch in Google Scholar
  • 31 Singh R, Melvin P, Wachman EM. et al; PNQIN Collaborative of Massachusetts. Short term outcomes of neonatal opioid withdrawal syndrome: a comparison of two approaches. J Perinatol 2024; 44 (08) 1137-1145
    CrossrefPubMedSearch in Google Scholar
  • 32 Henkhaus LE, Buntin MB, Henderson SC, Lai P, Patrick SW. Disparities in receipt of medications for opioid use disorder among pregnant women. Subst Abus 2022; 43 (01) 508-513
    CrossrefPubMedSearch in Google Scholar
  • 33 Sanjanwala AR, Lim G, Krans EE. Opioids and opioid use disorder in pregnancy. Obstet Gynecol Clin North Am 2023; 50 (01) 229-240
    CrossrefPubMedSearch in Google Scholar
  • 34 Englander H, Thakrar AP, Bagley SM, Rolley T, Dong K, Hyshka E. Caring for hospitalized adults with opioid use disorder in the era of fentanyl: a review. JAMA Intern Med 2024; 184 (06) 691-701
    CrossrefPubMedSearch in Google Scholar
  • 35 Hughto JMW, Tapper A, Rapisarda SS. et al. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs. Subst Abuse Treat Prev Policy 2023; 18 (01) 30
    CrossrefPubMedSearch in Google Scholar
  • 36 Lennox R, Patel T, Marmel A, Shaw E. Prenatal care outcomes in women with substance use disorders: a retrospective cohort study. J Obstet Gynaecol Can 2021; 43 (07) 850-855
    CrossrefPubMedSearch in Google Scholar